of lipid rafts in the entry of HIV-1 into podocytes. Conditionally immortalized human podocytes were exposed to primary strains of HIV-1 with different co-receptor usage-R5 HIV-1 92US660 and X4 HIV-1 92HT599 . As shown in Figure 1a , human podocytes exposed to either R5 or X4 viral strains were positive for HIV-1-specific strong-stop DNA (LTR RU5).
To determine the role of lipid rafts, we evaluated the effect of methyl-b-cyclodextrin (MbCD) on podocyte HIV-1 entry. MbCD is a derivative of cyclic oligosaccharides and has a lipophilic property that extracts cholesterol from membranes, resulting in lipid rafts disruption. 7 To test the drug effect of MbCD on mock-infected podocytes, we used the cholera toxin B-subunit, a specific marker for the lipid rafts associated GSL GM1. 8 MbCD treatment decreased approximately 70% podocyte cholesterol expression ( Figure 1b) . As shown in Figure 1c , podocyte viral accumulation significantly decreased after MbCD treatment when compared with the mock-treated control. As cholesterol-replenished cells (first exposed to cyclodextrin and then replenished with exogenous water-soluble cholesterol) showed comparable levels of viral entry (as observed in untreated cells), it appeared that the inhibition of HIV-1 entry was not due to the potential toxicity of MbCD (Figure 1d ). Inhibition of viral entry after cholesterol extraction was independent of viral tropism (data not shown). These results support the notion that cholesterol (maintenance of lipid raft integrity) is required for entry of both X4 and R5 HIV-1.
Response to 'HIV-1 entry into human podocytes is mediated through lipid rafts' The study by Mikulak and Singhal 1 showing the importance of cholesterol in the HIV infection of a human renal podocyte model system provides additional support for the important role of cell membrane 'lipid rafts' in HIV infection. Our studies on the binding of R5 gp120 within the human nephron showed that binding was restricted to tubular epithelial cells. gp120-tubular cell binding could be eliminated by detergent extraction of the sections, suggesting that binding occurred within the non-DRM ('nonraft') fraction. Although podocytes were not specifically identified in our study, the lack of gp120 glomerular binding we found indicates that gp120-mediated HIV-podocyte binding must be significantly less than to renal tubular epithelial cells. 2 The lipid raft requirement for HIV infection has been contested, 3, 4 and it may be that the lipid raft requirement varies between HIV target cell types. In addition, our studies indicate that Gb 3 is a resistance factor against HIV infection 5 rather than a mediator of infection. Thus, there is a significant difference between gp120-cell membrane Gb 3 binding and HIV target cell infection. In addition, the known receptors/co-receptors for gp120 on T cells can be expressed within the non-DRM fraction and then recruited to detergent resistant membranes after gp120-viral target cell binding, 6 and so initial binding within the non-detergent resistant membrane fraction does not exclude a later role for cholesterol in HIV internalization. To the Editor: I have read with great interest the article published recently in your esteemed journal entitled 'The Oxford classification of IgA nephropathy: rationale, clinicopathologic correlations, and classification'. 1 This is a unique and huge effort by the members of the International IgA Nephropathy Working Group in trying to standardize the reporting of pathological criteria of importance in the prognostication of this most common form of primary glomerulopathy worldwide. 2 I have a few points to make regarding the nomenclature of this scheme. I understand that these are conceptual and related to nomenclature, rather than substantial and related to contents of the study, and that they merit some consideration by the worthy authors of this scheme. The points are as follows: (1) I believe this effort is not the so-called 'splitters' approach to classification of diseases, inasmuch as no artificial classes are defined and the cases are lumped into these. The approach adopted in this classification is more akin to the Revised European-American Classification of Lymphoid Neoplasms (REAL) by the World Health Organization 3 and is much more sensible. As such, its nomenclature could preferably be changed to 'consensus schema' or 'formulation' to truly reflect the unique endeavor and the methodology adopted in this effort, or else it could be changed to 'working classification' for the following reasons. (2) I also assume this is not an end point classification of IgA nephropathy (IgAN). There is certainly room for evolution, as the authors also agree in discussion, as more realistic validation studies are being carried out on a wide spectrum of cases in routine clinical practice in different parts of the world. Moreover, the contribution of immunofluorescence and electron microscopic studies has not been evaluated in this schema. It will be worth exploring this aspect of the study of IgAN to see if they add any value to mere light microscopic scoring of the renal biopsies adopted in this classification. The future will definitely see more molecular genetic studies further refining the crude prognostic criteria that we have at hand now and true prognostic classes of IgAN may emerge. Retention of the word 'classification' in the option of nomenclature of 'working classification' will prevent us from repenting in future for not using it, should this picture emerge in future. This approach has been successfully adopted by the Banff working classification of renal allograft pathology.
